Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Milestone Scientific Inc. Announces Agreement with Bitmedical AG to Distribute the CompuFlo® .
Milestone Scientific, Inc.January 11, 2021 GMT
ROSELAND, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has entered into an agreement with Bitmedical AG (“Bitmedical”) to distribute the CompuFlo® Epidural Instrument and CathCheck™ System, as well as related disposables in Switzerland and Austria. Bitmedical is a premier distributor of medical devices and equipment within Switzerland and Austria, supporting many of the leading global manufacturers in these markets.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, .
Victory Square Technologies Inc.January 11, 2021 GMT
Victory Square Health received Brazilian ANVISA approval for Safetest 15 Minute Covid-19 Rapid Test for distribution, sale, and usage in Brazil
The Safetest 15 Minute Covid-19 Rapid Test has a 96.6% Sensitivity, and can confirm whether one is currently infected with the Covid-19 virus or whether one was infected prior and unaware of the infection
On November 17th, 2020, the Company announced a strategic partnership with Molkom Pharmaceuticals to sell and distribute its Safetest Covid-19 Rapid and other Tests in Brazil and for export to Mercosur Countries
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device
Cannabix Technologies Inc.January 12, 2021 GMT
VANCOUVER, British Columbia, Jan. 12, 2021 (GLOBE NEWSWIRE) Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
Press release content from Accesswire. The AP news staff was not involved in its creation.
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
January 12, 2021 GMT
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).